Benzinga on MSN: From lungs to nasal polyps: Sanofi finds success with 2-in-1 inflammation blocker Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, highlighting meaningful improvements in asthma and nasal polyp patients, while ... From lungs to nasal polyps: Sanofi finds success with 2-in-1 inflammation blocker Yahoo: For people with nasal polyps, new asthma drug may offer hope PHOENIX – Patients who have nasal polyps appeared to get symptom relief when treated with omalizumab (Xolair) regardless of comorbid asthma, according to a post-hoc trial analysis. All patients taking ...
GSK (LSE:GSK) has received Chinese regulatory approval for Exdensur (depemokimab) as the first ultra long acting biologic for adults with chronic rhinosinusitis with nasal polyps. The approval in ... The American Journal of Managed Care: Immunoglobulin Levels Linked With Nasal Polyp Development Local immunoglobulin levels were found to be significantly higher in polyp tissue specimens, but not in the blood, of patients with nasal polyps. Nasal polyp development may be associated with ...
nasal polyp, The American Journal of Managed Care: Several Postsurgery Prognostic Factors Linked With Nasal Polyp Recurrence Polyp recurrence occurred in more than 1 in 3 patients with chronic rhinosinusitis with nasal polyps who underwent endoscopic sinus surgery, with several prognostic factors linked with recurrence. Healio: Chronic rhinosinusitis with nasal polyps improves in 24 weeks with two verekitug doses Chronic rhinosinusitis with nasal polyps improves in 24 weeks with two verekitug doses For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...
